CD8A and neoplasm: IL12-MSA binding by tumor-reactive CD8+ T cells was increased by IL2-MSA, and combined IL12-MSA and IL2-MSA resulted in tumor-reactive CD8+ T cell effector differentiation and increased lung tumor control.